Sequence: Ac-RXRRBRRXRYQFLIRXRBRXRB-acid (B=β-alanine; X=aminohexanoic acid)
Morpholino ASO (Vivo-morpholino / PMO)
| Experiment Id | EXP000809 |
|---|---|
| Paper | Targeting IgE polyadenylation signal with antisense oligonucleotides decreases IgE secretion and pla |
| Peptide | Pip6a |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 6 µM (Pip6a-ASO, 24 h) |
| Mixing Ratio | |
| Formulation Format | CPP-conjugated ASO |
| Formulation Components | Pip6a peptide conjugated to 3′ end of vivo-morpholino IgE-PAS ASO (Pip6a-ASO) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U266 human myeloma cells (IgE-secreting) |
| Animal Model | |
| Administration Route | |
| Output Type | IgE concentration in supernatant |
| Output Value | |
| Output Units | |
| Output Notes | Pip6a-ASO decreased IgE secretion vs control ASO; reported as similar magnitude to octa-guanidine dendrimer conjugate (Fig 5A). Exact numeric values not provided in text. |
| Toxicity Notes | Apoptosis was shown for IgE-ASO (octa-guanidine conjugate) in U266; Pip6a-ASO apoptosis not explicitly quantified. |
| Curation Notes |